Skip to main content
Top
Published in: Supportive Care in Cancer 7/2008

01-07-2008 | Original Article

Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients

Authors: Luciano de Souza Viana, José Carlos Serufo, Manoel Otávio da Costa Rocha, Renato Nogueira Costa, Roberto Carlos Duarte

Published in: Supportive Care in Cancer | Issue 7/2008

Login to get access

Abstract

Goals of work

This is a prospective and observational study comparing the efficacy of risk-assessment models in patients with neutropenic fever in a reference treatment center. The meaning of the complex infection was evaluated.

Materials and methods

Patients were recruited throughout a 9-month period. Inclusion criteria were histologic diagnosis of malignancy, neutropenic febrile secondary to chemotherapy and/or radiotherapy (absolute neutrophil count of <500/µl and axillary temperature ≥38°C), and ≥18 years of age.

Main results

Fifty-three febrile neutropenic patients were included. Twenty one of them were classified as low risk by the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the MASCC risk-index scores were, respectively 87.9, 85.0, 90.6, 80.9, and 86.8%. None of the low-risk patients died, but four patients classified as low risk by the MASCC model developed serious medical complications during febrile neutropenic episodes. When we subtracted patients with complex infections from the group of patients with the MASCC risk-index score of ≥21, we got 15 patients that were classified as low risk by a proposed adjustment by complex infection (PACI) model. None of them developed serious medical complications. The sensitivity, specificity, PPV, NPV, and the accuracy of this new model were, respectively, 100, 75.0, 86.8, 100, and 90.6%.

Conclusion

The MASCC risk-index score had high sensitivity and specificity to predict the absence of complications, but the PACI model was better than MASCC for predicting the absence of complications in this febrile neutropenic patients.
Literature
1.
go back to reference Chamilos G, Bamias A, Efstathiou E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103(12):2629–2635PubMedCrossRef Chamilos G, Bamias A, Efstathiou E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103(12):2629–2635PubMedCrossRef
2.
go back to reference Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed
3.
go back to reference Donowitz GR, Maki DG, Crnich CJ, et al (2001) Infections in the Neutropenic Patient - New Views of an Old Problem. In: ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, 43TH., 2001, Orlando. Education Program Book: Hematology (Am Soc Hematol Educ Program):113–139 Donowitz GR, Maki DG, Crnich CJ, et al (2001) Infections in the Neutropenic Patient - New Views of an Old Problem. In: ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, 43TH., 2001, Orlando. Education Program Book: Hematology (Am Soc Hematol Educ Program):113–139
4.
go back to reference Elting LS, Rubenstein EB, Rolston KV et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259PubMedCrossRef Elting LS, Rubenstein EB, Rolston KV et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259PubMedCrossRef
5.
go back to reference Escalante CP, Weiser MA, Manzullo E et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12(9):657–662PubMed Escalante CP, Weiser MA, Manzullo E et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12(9):657–662PubMed
6.
go back to reference Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef
7.
go back to reference Kern WV (2006) Risk assessment and treatment for low-risk patients with febrile neutropenia. Clin Infect Dis 42(4):533–540PubMedCrossRef Kern WV (2006) Risk assessment and treatment for low-risk patients with febrile neutropenia. Clin Infect Dis 42(4):533–540PubMedCrossRef
8.
go back to reference Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed
9.
go back to reference Nijhuis CO, Kamps WA, Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23(30):7437–7444CrossRef Nijhuis CO, Kamps WA, Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23(30):7437–7444CrossRef
10.
go back to reference Paesmans M (2000) Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 16(2):107–111PubMedCrossRef Paesmans M (2000) Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 16(2):107–111PubMedCrossRef
11.
go back to reference Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113PubMedCrossRef Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113PubMedCrossRef
12.
go back to reference Rolston KV (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29(6):551–554PubMedCrossRef Rolston KV (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29(6):551–554PubMedCrossRef
13.
go back to reference Rolston KV (1999) New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29(3):515–521PubMedCrossRef Rolston KV (1999) New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29(3):515–521PubMedCrossRef
14.
go back to reference Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561–2568PubMedCrossRef Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561–2568PubMedCrossRef
15.
go back to reference Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555–560PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555–560PubMedCrossRef
Metadata
Title
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
Authors
Luciano de Souza Viana
José Carlos Serufo
Manoel Otávio da Costa Rocha
Renato Nogueira Costa
Roberto Carlos Duarte
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0347-3

Other articles of this Issue 7/2008

Supportive Care in Cancer 7/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine